AdvaMed is the leading medtech industry conference in North America. From October 17-19, 2016 Minneapolis will host thousands of medtech industry leaders gathered together in a multifaceted environment for business development, capital formation, technology showcasing, world-class educational opportunities and networking. GCMI was founded upon, and still operates with, the goal of providing necessary resources and…
Now more than ever, physician innovators entering into the medical device ecosystem are experiencing a highly regulated and cost constrained environment. Maneuvering through this world is not for the faint of heart and takes more than sheer will: it takes a multidisciplinary team. Navigating the journey from concept to commercialization for novel new products and…
“When I moved here, I noticed Atlanta seemed to be very siloed with everyone trying to do their own thing.What I’ve seen over the last five years is the breaking down of those silos.” Through the lens of Atlanta’s innovation ecosystem, GCMI CEO Tiffany Wilson recently spoke with Hypepotamus’ Kristyn Back about the rigors…
Now more than ever, physician innovators are entering into a highly regulated and cost constrained environment. “This industry is not for the faint of heart,” says Rafael Andino, Vice President of Engineering and Manufacturing for Clearside Biomedical, Inc. Andino is part of a team of innovators that built a biopharmaceutical company from concept to clinical…
GCMI is a multifunctional tool. This is made apparent by stories like Hunter Moyer’s with Vivid LED technologies. Before finding and engaging GCMI he had already conceptualized a new medtech product, built a prototype, and then found himself asking “What’s next?” That is where GCMI stepped in. The desire to better existing technologies for facial…
Read how GCMI and T3 worked together to help John Erbey at Strataca develop a new way to manage Acute Kidney Injury (AKI)
Preclinical medical device testing: how do you know you are ready and how do you make the most efficient investment in preclinical?